Sanjay Kalra and Psychiatrist Yatan Pal Singh Balhara question whether “diabetes distress” is well understood outside of the diabetes field and consider whether alternative terminology may help to bridge the knowledge gap.
The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.
Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.
Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.
Giving pregnant obese women metformin in addition to dietary and lifestyle advice does not reduce the likelihood of them having a baby with a high birthweight, show the results of the GRoW randomized trial.
The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.
Sanjay Kalra and Psychiatrist Yatan Pal Singh Balhara question whether “diabetes distress” is well understood outside of the diabetes field and consider whether alternative terminology may help to bridge the knowledge gap.
A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.
